These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 10438702)

  • 21. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma.
    Rimoldi D; Rubio-Godoy V; Dutoit V; Lienard D; Salvi S; Guillaume P; Speiser D; Stockert E; Spagnoli G; Servis C; Cerottini JC; Lejeune F; Romero P; Valmori D
    J Immunol; 2000 Dec; 165(12):7253-61. PubMed ID: 11120859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
    Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new tumor-specific antigenic peptide encoded by MAGE-6 is presented to cytolytic T lymphocytes by HLA-Cw16.
    Vantomme V; Boël P; De Plaen E; Boon T; van der Bruggen P
    Cancer Immun; 2003 Dec; 3():17. PubMed ID: 14664500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses.
    Breckpot K; Heirman C; De Greef C; van der Bruggen P; Thielemans K
    J Immunol; 2004 Feb; 172(4):2232-7. PubMed ID: 14764691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.
    Krishnadas DK; Wang Y; Sundaram K; Bai F; Lucas KG
    Tumour Biol; 2017 Jul; 39(7):1010428317701309. PubMed ID: 28677424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antigen-specific in vitro expansion of functional redirected NY-ESO-1-specific human CD8+ T-cells in a cell-free system.
    Jakka G; Schuberth PC; Thiel M; Held G; Stenner F; Van Den Broek M; Renner C; Mischo A; Petrausch U
    Anticancer Res; 2013 Oct; 33(10):4189-201. PubMed ID: 24122982
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells.
    Tarte K; Zhang XG; Legouffe E; Hertog C; Mehtali M; Rossi JF; Klein B
    J Immunol; 1999 Jul; 163(1):514-24. PubMed ID: 10384156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer testis antigen, ropporin, is a potential target for multiple myeloma immunotherapy.
    Chiriva-Internati M; Mirandola L; Yu Y; Jenkins MR; Gornati R; Bernardini G; Gioia M; Chiaramonte R; Cannon MJ; Kast WM; Cobos E
    J Immunother; 2011; 34(6):490-9. PubMed ID: 21654522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes.
    Boël P; Wildmann C; Sensi ML; Brasseur R; Renauld JC; Coulie P; Boon T; van der Bruggen P
    Immunity; 1995 Feb; 2(2):167-75. PubMed ID: 7895173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96.
    Qian J; Wang S; Yang J; Xie J; Lin P; Freeman ME; Yi Q
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8808-15. PubMed ID: 16361569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma.
    Batchu RB; Moreno AM; Szmania SM; Bennett G; Spagnoli GC; Ponnazhagan S; Barlogie B; Tricot G; van Rhee F
    Cancer Res; 2005 Nov; 65(21):10041-9. PubMed ID: 16267030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients.
    Yang D; Nakao M; Shichijo S; Sasatomi T; Takasu H; Matsumoto H; Mori K; Hayashi A; Yamana H; Shirouzu K; Itoh K
    Cancer Res; 1999 Aug; 59(16):4056-63. PubMed ID: 10463607
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new MAGE gene with ubiquitous expression does not code for known MAGE antigens recognized by T cells.
    Lucas S; Brasseur F; Boon T
    Cancer Res; 1999 Aug; 59(16):4100-3. PubMed ID: 10463614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells.
    Carbone E; Neri P; Mesuraca M; Fulciniti MT; Otsuki T; Pende D; Groh V; Spies T; Pollio G; Cosman D; Catalano L; Tassone P; Rotoli B; Venuta S
    Blood; 2005 Jan; 105(1):251-8. PubMed ID: 15328155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells.
    Mandic M; Almunia C; Vicel S; Gillet D; Janjic B; Coval K; Maillere B; Kirkwood JM; Zarour HM
    Cancer Res; 2003 Oct; 63(19):6506-15. PubMed ID: 14559844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity.
    Krönig H; Hofer K; Conrad H; Guilaume P; Müller J; Schiemann M; Lennerz V; Cosma A; Peschel C; Busch DH; Romero P; Bernhard H
    Int J Cancer; 2009 Aug; 125(3):649-55. PubMed ID: 19444908
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Khalaf WS; Garg M; Mohamed YS; Stover CM; Browning MJ
    Front Immunol; 2019; 10():1792. PubMed ID: 31428094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy.
    Maruta M; Ochi T; Tanimoto K; Asai H; Saitou T; Fujiwara H; Imamura T; Takenaka K; Yasukawa M
    Sci Rep; 2019 Sep; 9(1):13293. PubMed ID: 31527633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of a MAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-B*5701 tumors.
    Corbière V; Nicolay H; Russo V; Stroobant V; Brichard V; Boon T; van der Bruggen P
    Tissue Antigens; 2004 May; 63(5):453-7. PubMed ID: 15104676
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer.
    Sharma P; Gnjatic S; Jungbluth AA; Williamson B; Herr H; Stockert E; Dalbagni G; Donat SM; Reuter VE; Santiago D; Chen YT; Bajorin DF; Old LJ
    Cancer Immun; 2003 Dec; 3():19. PubMed ID: 14680360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.